Hamed Bagheri, the managing director of an Iranian knowledge-based company, said that the heart attack diagnosis kit, as one of the products made in his company, can save the country $6 million each year to import it.
“Now, we are capable to locally produce the kit and selling to the costumers gaining more than 10% of the market share in the last 10 months,” he went on to say.
He said that one of the competitive advantages of their product compared to foreign equivalents is the lower cost due to acquiring its technical knowledge by the company's researchers and stated, “This product's price is 20% lower than Chinese counterpart and this has helped us to take market share from importers.”
“After a heart attack, the cardiac troponin marker (cTnI) is released into the blood by the damaged heart muscle. The level of this marker remains high between 6 and 10 days after the injury and is used as a marker to diagnose a heart attack,” he said.
“Troponin is present in the cardiac muscle, and together with troponin T and troponin C, it forms a three-subunit complex, and this complex, together with tropomyosin, plays a vital role in transmitting contraction signals in skeletal muscles. Following heart tissue injury due to myocardial infarction, troponin is released into the blood 4 to 6 hours after the start of pain, and its concentration remains high for 6 to 10 days.”
"This test assesses the presence of more than normal amounts of this substance in whole blood, serum or plasma samples with a simple and quick method and detects the positive samples in a qualitative way that could be detected with eye," Bagheri concluded.